I last reviewed Moody's Corporation (MCO) in this July 26, 2022 post at which time MCO had just released Q2 and YTD2022 results. Based on this analysis of MCO's Q4 and FY2022 results and FY2023 outlook released on January 31, 2023, I am not adding to my exposure because the current valuation is not justified. [...]
I last reviewed CVX in my August 18, 2022 guest post at Dividend Power at which time I concluded that the oil and gas demise was overblown. Following the January 27 release of Chevron's (CVX) exceptional FY2022 results, there appears to be a bit too much euphoria. This certainly was evident when CVX announced its [...]
I wrote a brief Blackstone (BX) post on December 1 in which I share why negative headlines leading to a decline in BX's share price present investors with a buying opportunity. When investing in BX, however, an investment must be for the long term. I say this because of the recent intense focus on the [...]
I last reviewed Automatic Data Processing (ADP) in my October 31, 2022 post at which time Q1 results and the revised FY2023 outlook had just been released. Based on my analysis I deemed ADP to be slightly overvalued. On January 25, ADP released Q2 and YTD2023 results and provided an update to its FY2023 outlook. [...]
I last reviewed Lockheed Martin (LMT) in this October 18, 2022 post. LMT has now released Q4 and FY2022 results and its FY2023 outlook on January 24. Despite supply chain headwinds, growth in the order backlog is encouraging. In this post, I look at whether I should add to my LMT exposure. I have also [...]
I last reviewed Raytheon Technologies (RTX) in this July 27, 2022 post. With the January 24, 2022 release of Q4 and FY2022 results and FY2023 outlook, I revisit it to determine whether I should add to my exposure. Business Overview Investors unfamiliar with RTX are encouraged to review the company's website and Part 1 Item [...]
In my most recent guest post contribution at Portfolio Insight, I share CME Group (CME) as my top dividend stock pick for 2023; my November 14, 2022 CME Group Is Low-Risk and Attractively Valued post goes into more detail as to why I invest in this company. The request was for a very brief write-up [...]
In my Scotiabank (BNS) Is A Terrible Long-Term Investment post at Dividend Power, I explain why investors might want to cast their net wider. I last reviewed Scotiabank (BNS) in my August 25, 2022 'Avoid Scotiabank Despite Its Attractive Valuation' post on this site. In the Final Thoughts segment of that post, I indicate that [...]
On January 17, 2023, Goldman Sachs (GS) reported weaker-than-anticipated Q4 and FY2022 results because of high expenses and weak Investment Banking revenue. Despite measures having been implemented to improve results, I am cautiously optimistic GS will experience further short-term share price weakness. I last reviewed this holding in my July 8, 2022 post at [...]
At the time of my last Danaher (DHR) post, it had recently released its Q3 and YTD2022 results. I concluded that I plan to slowly increase my exposure given that its credit risk is improving and its current valuation and long-term outlook are attractive. I now disclose an increase in my Danaher exposure in the [...]